ERK has long been associated with malignant transformation in various cancers including CRC, with upstream KRAS/BRAF harbouring driver mutations.6,8,17 Therefore, it is interesting that this improvement in patient survival is specific to BRAF- mutant tumours, with strong activation of ERK. Here, KRAS is linked to colorectal carcinoma.